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Abstract (294 words) 40 
Background 41 
We evaluated the acceptability, feasibility and outcomes of rapid ART initiation in the 42 
Botswana Combination Prevention Project (BCPP). 43 
Methods 44 
BCPP was a community-randomized HIV-prevention trial performed from 2013-2018. In June 45 
2016 universal HIV-treatment and rapid ART initiation with dolutegravir-based ART were 46 
introduced; same-day ART initiation was offered at the first clinic visit. We determined time 47 
to ART initiation, and rates of retention in care and viral suppression at one year.  48 
Findings  49 
1,717 eligible adults linked to study clinics prior to and 800 after rapid ART introduction. 50 
During the rapid ART period 57.1% (95% confidence interval [CI] 53.7-60.6%) of linked 51 
individuals initiated ART within 1 day of linkage, 73.7% (95%CI 70.6-76.7%) within 1 week 52 
of linkage, 84.9% (95%CI 82.4-87.3%) within 1 month, and 93.5% (95%CI 91.6-95.1%) 53 
within 1 year. Prior to the introduction of rapid ART 16.1% (95%CI 14.4-17.9%) of linked 54 
individuals initiated ART within 1 week of linkage, 48.9% (95%CI 46.5-51.3%) within 1 55 
month, and 89.2% (95%CI 87.7-90.6%) within 1 year. One year after ART initiation 90.5% 56 
(95%CI 87.4%-92.8%) of individuals who linked in the standard ART period were in care and 57 
had a viral load <400 copies/ml, compared to 91.6% (95%CI 88.1%-94.1%) in the rapid ART 58 
period (odds ratio 1.20, 95%CI 0.86-1.67, p=0.294). Median time from linkage to documented 59 
viral suppression was 99 days following introduction of rapid ART initiation (interquartile 60 
range [IQR] 86-166 days) compared to 186 days (IQR 116-323 days) prior to rapid ART 61 
(p<0.001).  62 
Interpretation 63 
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Simplified rapid ART initiation with the offer of same-day ART to individuals led to high rates 64 
of ART initiation, and significantly reduced time from linkage to starting ART and to 65 
virological suppression. Rates of retention in care and viral suppression after one-year of ART 66 
were high.  67 
Funding 68 
US President’s Emergency Plan for AIDS Relief. 69 
 70 
  71 
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Introduction 72 
Ensuring that individuals who are diagnosed with HIV infection rapidly initiate ART is a 73 
critical step in meeting the Joint United Nations Programme on HIV/AIDS (UNAIDS) 90-90-74 
90 targets;1,2 however, data from low- and middle-income (LMIC) settings have demonstrated 75 
high rates of loss from the care cascade between HIV testing and ART initiation, or substantial 76 
delays to initiation of treatment.2-8 Many of these losses result from significant barriers to ART 77 
initiation including the need for multiple clinic visits, repeated pre-ART counselling sessions, 78 
and delays in receiving baseline blood test results.9-15 A potential way to increase rates of ART 79 
initiation is to offer same-day ART to all individuals at their initial clinic visit - a strategy that 80 
became more feasible following the elimination of baseline CD4 testing to determine treatment 81 
eligibility as well as the transition to a dolutegravir (DTG)-containing first-line ART 82 
regimen.16,17   83 
Several randomized controlled trials from LMICs have shown that rapid ART initiation 84 
is acceptable and feasible, and can increase rates of ART initiation, retention in care, and 85 
virological suppression.18-21 In 2017 the WHO updated treatment guidance  to recommend 86 
rapid ART initiation (7 days) with the offer of same-day ART initiation in all individuals who 87 
were ready to start treatment.16 However, prior trials included enhancements to care beyond 88 
changes to ART timing, and also included CD4-based eligibility criteria, potentially limiting 89 
their generalizability.2,22,23 Concerns also exist about ongoing retention in care after rapid ART 90 
initiation in patients with high CD4.22,24 91 
We were able to evaluate the acceptability, feasibility and outcomes of rapid ART 92 
initiation with the offer of ART at first clinic visit in public sector ART clinics in Botswana in 93 
the context of the cluster-randomized Botswana Combination Prevention Project (BCPP).25 94 
 95 
METHODS  96 
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Study design and participants. BCPP was a cluster-randomized HIV prevention trial. A full 97 
description of the study design is available elsewhere.25 Study interventions included intensive 98 
HIV-testing campaigns, linkage-to-care interventions, and expanded ART, including universal 99 
DTG-containing ART starting in 2016. The interventions were conducted in 15 rural or peri-100 
urban community clusters, while 15 matched control community clusters received standard of 101 
care services. Average community population was approximately 6,000 individuals. This 102 
analysis is restricted to persons identified as HIV positive, not on ART, who were referred for 103 
treatment in the 15 study intervention communities. 104 
Study procedures.  Study interventions took place between October 2013 and March 2018.  All 105 
16-64 year-old community residents identified through community testing activities were 106 
assessed through a standard intake questionnaire and asked if they were HIV-positive. Persons 107 
who did not know their status, did not have documentation of an HIV-positive status, or did 108 
not have documentation of a negative HIV test within the preceding 3 months were offered 109 
rapid HIV-testing using KHB (KHB, Shanghai Kehua Bio-Engineering Co Ltd, Shanghai, 110 
China) and Unigold (Trinity Biotech Plc, Bray, Ireland) parallel HIV tests. Discordant reults 111 
were verified by laboratory testing using western blot. All participants provided verbal consent 112 
for HIV testing.  113 
All newly-identified and known HIV-positive persons not on ART were referred to 114 
their local Ministry of Health community clinic for ART initiation and provided with linkage 115 
support services. Prior to the introduction of rapid ART initiation, all HIV-infected individuals 116 
not on ART had a point-of-care (POC) CD4 count (PIMA™ CD4, Alere, Inc. Waltham, MA, 117 
USA) at the initial community intake contact. ART was initiated (1) when an individual’s CD4 118 
was <350 cells/microliter (µL) or they met criteria for WHO clinical stage III or IV, based on 119 
Botswana’s national guidelines; or (2) if they met the BCPP expanded ART eligibility criteria 120 
of CD4 <500 cells/µL or CD4 >500 cells/µL and viral load (VL) > 10,000 copies/µL (Abbott 121 
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RealTime HIV-1 assay on the automated m2000 system, Abbott Laboratories, Wiesbaden, 122 
Germany). Standard procedures for ART initiation required 3 adherence counselling visits and 123 
baseline laboratory tests to be drawn and reviewed, thus requiring at least three clinic visits 124 
before ART initiation occurred. First-line therapy consisted of tenofovir, emtricitabine, and 125 
efavirenz as a single combination tablet.  126 
Starting in June 2016, all HIV-infected persons were eligible and referred for ART, 127 
regardless of CD4 count or disease stage. Baseline VL testing and POC CD4 testing were 128 
discontinued. The first-line regimen changed to tenofovir and emtricitabine as a combination 129 
tablet, plus DTG. In the intervention arm we concurrently introduced rapid ART initiation, 130 
aiming to start ART within 7 days of HIV testing (or 7 days of referral to the clinic, for persons 131 
who already knew their positive HIV status), with the offer of same-day ART initiation at first 132 
clinic visit. Baseline blood tests including CD4 counts were taken at the initial clinic visit, but 133 
providers were not required to await results prior to ART initiation. No additional changes to 134 
baseline clinical assessment or opportunistic infection screening algorithms were made.  135 
For the duration of the study patients were seen 2 weeks following ART initiation for 136 
clinical review, then 3 months after ART initiation for VL testing. Clinic appointments with 137 
VL testing were then performed 6-monthly thereafter, unless the initial VL was not suppressed 138 
in which case patients would undergo repeat VL testing 3 months later. CD4 testing was 139 
performed at baseline then annually unless the initial CD4 count was <200 cells/µL, in which 140 
case it was repeated after 6 months.  141 
The study was approved by the Centers for Disease Control and Prevention Institutional 142 
Review Board (Protocol #6475) and the Botswana Health Research and Development 143 
Committee. The study was monitored by an Independent Data and Safety Monitoring Board, 144 
and prospectively registered at ClinicalTrials.gov, number NCT01965470. 145 
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Outcomes. Primary outcome measures were (1) time from first eligible ART clinic visit to 146 
ART initiation, and (2) rates of retention in care and viral suppression (defined as a plasma VL 147 
<400 copies/µL) at 1 year post-ART initiation. Given the potential for patients to have viral 148 
load testing at either 9 months or 12 months depending on viral suppression status at month 3, 149 
and to allow for delays in clinic attendance, a 90-day window was placed around the 1 year VL 150 
timepoint. Patients were considered lost to follow-up if they had not attended any HIV-related 151 
clinic activity within 180 days of data censoring on 28th June 2018.  Secondary outcomes 152 
included uptake of ART within 1 year of linkage, time from ART clinic linkage to HIV viral 153 
suppression, and mortality within 1 year of linkage.   154 
Statistical analysis. Analysis was restricted to study participants in the 15 intervention clusters 155 
linking to care at a Ministry of Health facility. Data were analysed using Stata version 14 156 
(StataCorp, College Station, TX). The standard ART care cohort included any individual 157 
eligible for ART and linking to a clinic prior to June 1st 2016. The rapid ART start cohort 158 
included all individuals linking  a clinic from June 1st 2016 onwards following introduction of 159 
universal ART and rapid ART initiation guidelines. Data were summarised using frequencies 160 
and proportions with robust 95% confidence intervals (CI) adjusted for clustering by 161 
community, and medians and interquartile ranges (IQRs). Rates of ART initiation were 162 
compared between groups using a hierarchical Cox proportional hazards model accounting for 163 
clustering by community through inclusion of a random-effects term. Adjusted analyses were 164 
performed stratified by age, sex, CD4 count, and whether individuals were newly diagnosed 165 
with HIV or had a previously known diagnosis. An interrupted time series analysis using 166 
monthly aggregated ART timing data was performed using the “itsa” function in Stata26. Rates 167 
of retention in care and virological suppression at 1 year were summarized using proportions 168 
with robust 95% CIs adjusted for clustering by community, and compared between groups 169 
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using a hierarchical mixed effects regression model incorporating a random effects term for 170 
community. P-values of <0.05 were considered to be statistically significant. 171 
Role of the funding source. The study was funded by the US President’s Emergency Plan for 172 
AIDS Relief. The funders had no direct role in study design, in the collection, analysis, and 173 
interpretation of data, in the writing of this report, or in the decision to submit it for publication. 174 
The corresponding author (JNJ) had full access to all the data in the study and had final 175 
responsibility for the decision to submit for publication. 176 
 177 
Results 178 
Between October 2013 and March 2018, BCPP research staff assessed HIV status in 61,655 179 
community residents, of whom 13,328 (22%) were HIV infected. Of these, 3,657 (27%) were 180 
not on ART; 3,282 (89.7% ) linked to care at an ART clinic a median of 6 days (IQR 3-35 181 
days) after community assessment. Three hundred and seventy four individuals linked to clinics 182 
outside the intervention communities and did not have reliably documented linkage or ART 183 
initiation dates and were excluded from further analysis. Of the remaining 2,908 individuals 184 
included in the final analysis 2,108 linked during the standard ART period of whom 1,717 185 
(81.5%) were eligible for ART initiation, and 800 linked after the introduction of rapid ART 186 
initiation when all HIV-positive individuals were eligible for ART (Figure 1). Baseline 187 
characteristics of study participants are shown in Table 1. 188 
ART uptake and time to ART initiation following linkage 189 
ART initiation occurred significantly more rapidly following the introduction of rapid 190 
ART guidelines in June 2016 (Figure 2a, p<0.001 in unadjusted and adjusted hierarchical Cox 191 
proportional hazards model). During the rapid ART period 57.1% (457) of linked individuals 192 
initiated ART within 1 day of linkage, 73.7% (589) initiated within 1 week of linkage, 80.3% 193 
(641) within 2 weeks, and 84.9% (678) within 1 month; overall, 93.5% (744) of individuals 194 
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had initiated ART within the first year following linkage during the rapid ART period. Prior to 195 
the introduction of rapid ART initiation guidelines 16.1% (276) of linked individuals initiated 196 
ART within 1 week of linkage, 29.1% (499) within 2 weeks, and 48.9% (839) within 1 month; 197 
Overall, 89.2% (1,532) of individuals had initiated ART within the first year following linkage. 198 
Analyses stratified by prior HIV status (new or known), sex, age, and baseline CD4 count are 199 
shown is supplementary figure S1. 200 
Interrupted time series analysis using log-transformed monthly aggregate data showed 201 
a non-significant downwards trend in ART initiation timing during the standard ART initiation 202 
period (ß coefficient -0.009 log10days per month, 95% CI -0.018-0.0004, p=0.062), and a 203 
significant decline during the rapid ART initiation period (ß coefficient -0.023 log10days per 204 
month, 95% CI -0.034-0.011, p<0.001). There was a significant decrease in time from linkage 205 
to ART initiation in the month following introduction of rapid ART initiation guidelines (∆=-206 
0.78 log10days, 95% CI -0.93- -0.63 log10days, p<0.001)(Figure 2b).  207 
Retention in care and viral suppression following ART initiation 208 
Retention in care at 1 year following ART initiation (limited to those individuals 209 
initiating ART at least 1 year prior to data censoring), and rates of viral suppression are shown 210 
in Figure 3. Retention in care was 98.4% (1601/1627) at 1 year among individuals who linked 211 
prior to introduction of rapid ART initiation guidelines and initiated ART, and 96.9% (610/631) 212 
among individuals linking to care and initiating ART following introduction of rapid ART. 213 
One-year VL results were available for 92.7% (1509/1627) of individuals who linked and 214 
initiated ART in the standard ART period and 93.8% (592/631) of patients initiating during the 215 
rapid ART period, with viral suppression rates of 97.5% and 97.6% respectively. Overall, 216 
90.5% (1472/1627, 95% CI 87.4% - 92.8%) of individuals who linked in the standard ART 217 
period and initiated ART were in care and had a documented VL <400 copies/ml after 1 year 218 
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of ART, compared to 91.6% (578/631, 95% CI 88.1% - 94.1%) of individuals who linked in 219 
the rapid ART period and initiated ART (odds ratio[OR] 1.20, 95%CI 0.86-1.67, p=0.294).  220 
Time from linkage to viral suppression 221 
Median time from linkage to documented viral suppression was significantly shorter 222 
following the introduction of rapid ART initiation guidelines, at 99 days (IQR 86-166 days) 223 
compared to 186 days (IQR 116-323 days) prior to rapid ART (p<0.001). In the group linking 224 
prior to the introduction of rapid ART 74.3% (1,276/1,717) had achieved virological 225 
suppression within a year of linkage, compared to 82.9% (663/800) following the introduction 226 
of rapid ART (p<0.001). Median time from ART initiation to documented viral suppression 227 
was 112 days (IQR 84-194) during the standard ART period, and 93 days (IQR 82-139 during 228 
the rapid ART period, p<0.001.  229 
Safety of rapid ART initiation 230 
Twelve patients (1.5%) who initiated ART following the introduction of rapid ART 231 
guidelines were found to have pre-ART creatinine clearance <60mL/minute (Supplementary 232 
Table S1). Of these, 9 initiated ART within the first two weeks, 7 of whom started ART on the 233 
same-day (i.e. prior to availability of creatinine clearance results). Two of these 9 patients had 234 
been started on non-tenofovir-containing regimens (abacavir) due to a known history of renal 235 
impairment, three were switched to non-tenofovir containing regimens (abacavir) on receipt of 236 
renal function results, and four remained on tenofovir-based regimens with stable renal 237 
function. Two of the nine patients died during the first year of follow-up. One had been started 238 
on an abacavir-based regimen, and died of cervical carcinoma after 46 weeks of ART. The 239 
second started a tenofovir based regimen. Serum creatinine remained stable at 91 mmol/L at 240 
week 2, and the attending clinicians opted to maintain the patient on tenofovir. The patient died 241 
after 20 weeks of ART of unknown causes. Overall mortality in the year following linkage was 242 
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1.16% (20/1717) in the standard ART period, and 1.00% (8/800) in the rapid ART period 243 
(p=0.714).  244 
 245 
Discussion 246 
Simplified rapid ART initiation with the offer of same-day treatment at first ART clinic visit 247 
to all clinically-stable patients was acceptable and feasible in public ART clinics in Botswana, 248 
with over half of patients initiating ART within 1 day of ART clinic linkage and 74% initiating 249 
within 1 week. Following the introduction of rapid ART the proportion of patients established 250 
on ART increased from 49% to 85% at 1 month from clinic linkage, and from 89% to 94% at 251 
1 year. The median time from clinic linkage to viral suppression was significantly reduced, 252 
with potential contributions from both more rapid intiation of ART and the switch to DTG. 253 
Rates of retention in care and viral suppression were similarly high in individuals initiated on 254 
ART prior to the introduction of rapid ART and those initiated during the rapid ART period, 255 
with documented viral suppression after 1 year of ART in over 90% of individuals in both 256 
groups.  257 
Our findings add to the accumulating evidence demonstrating the feasibility, 258 
acceptability, and safety of rapid ART initiation in LMIC settings, and provide some of the 259 
first evidence for the acceptability among patients with high CD4 counts.3 Recent clinical trials 260 
from South Africa,18,27 Lesotho,21 Haiti,20 and Uganda19 have all shown the high uptake of 261 
same-day or rapid ART when offered to patients in clinic18-20,27 or community21 settings. In the 262 
RapIT trial in South Africa 72% of individuals offered rapid ART initiation initiated same-day, 263 
and 96% within one month.18 Similar figures were reported by Amanyire et al. from a cluster-264 
randomized trial in Uganda, where a clinic-level streamlined ART initiation intervention led to 265 
71% of individuals initiating on the day of eligibility, compared to 18% in the control arm. 266 
Even higher rates of 99% uptake of same day ART have been reported from a recent clinic 267 
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based rapid ART initiation trial in Haiti,20 and 98% of participants in a community-based trial 268 
in Lesotho indicated readiness for same-day ART.21 These very high rates of same-day 269 
initiation  (compared to 57% in our study) are generally in the context of selected populations; 270 
for example 21% (225/1054) patients in the South African study were deemed too sick to 271 
participate; the Ugandan study only included patients once they had had CD4 testing and 272 
clinical assessment and been deemed eligible for ART;19 and the Haitian study was also 273 
restricted to patients meeting clinical and CD4-based eligibility criteria.20   274 
Importantly, given potential concerns about attrition from care with rapid ART 275 
initiation, particularly in individuals with high CD4 counts who may not perceive the need for 276 
treatment such as those in PMTCT Option B-plus programs,22,24 our data also support the 277 
findings from these studies indicating that benefits of rapid ART initiation are sustained over 278 
time. Findings from the prior rapid ART studies in South Africa, Haiti Uganda, and Lesotho 279 
have all indicated either equivalent or increased retention in care and viral suppression with 280 
rapid ART when compared to standard models of ART delivery.18-21 Our finding of 90% 281 
documented retention and virological suppression at 1 year following ART initiation closely 282 
matches data from the recent SEARCH trial in Uganda and Kenya, showing 89% retention in 283 
care among patients newly linked to care and rapidly initiated on ART.28 284 
To the best of our knowledge, these are the first data reporting the outcomes of rapid 285 
ART initiation in a routine LMIC care setting, without baseline screening blood tests, POC 286 
CD4 counts, or additional assessment of asymptomtic patients. Although the safety of initiating 287 
ART whilst awaiting laboratory results has understandably been of concern to many clinicians2, 288 
we did not document adverse patient outcomes arising from either initiation of tenofovir-based 289 
therapy in the absence of a serum creatinine result, or the development of immune 290 
reconstitution inflammatory syndromes in patients with low CD4 counts. Mortality within 1 291 
year of linkage was low at 1% during both the standard ART and rapid ART periods.  292 
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The more rapid ART initiation and shorter time from linkage to viral suppression 293 
observed following implemetation of rapid DTG-based ART initiation in our study are likely 294 
to have both individual- and population-level benefits. HIV transmission risk is highly 295 
dependent on viral load,29 with convincing evidence for marked reductions in transmission to 296 
sexual partners in individuals on effective ART.30,31 It is also probable that rapid ART can 297 
confer individual-level health benefits, particularly among individuals with low CD4 cell 298 
counts (<200 cells/µL) who are at extremely high risk of mortality if ART is delayed for even 299 
a few weeks.32-34 We did not find a mortality reduction following rapid ART initiation in our 300 
setting, probably in part due to the relatively high median CD4 count at ART initiation. A 301 
further potential reason for the lack of an observed mortality benefit in our study is the fact that 302 
during the standard ART period individuals with low CD4 counts were identified with POC 303 
CD4 counts, which would not be the case in routine care, and rapidly initiated on ART, 304 
lessening the impact of the introduction of rapid ART initiation guidelines in our study.  305 
Our study had several limitations. Firstly, as a sub-analysis planned after initial protocol 306 
development we were unable to randomize patients to the rapid ART intervention. The group 307 
initiating rapid ART were more likely to be newly diagnosed with HIV, more likely to be men, 308 
and more likely to be younger; factors previously associated with worse uptake of HIV 309 
services.6,9,35-40 The before and after design also leads to the possibility of temporal 310 
confounding. Although there were no major changes in ART initiation procedures other than 311 
introduction of rapid ART during the study it is possible that clinic staff became more proficient 312 
at initiating patients as the study progressed; or that other study-specific or external factors 313 
influenced ART timing. The interrupted time series analysis, performed to examine this 314 
possibility, revealed no significant temporal trends in time to ART pre-rapid ART 315 
implementation. Additionally, as rapid ART was implemented during the latter half of the trial, 316 
participants in the rapid ART group did not have the same length of time as those in the standard 317 
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ART group to cycle back into care and be classified as on treatment after missing appointments, 318 
potentially leading to an underestimation of retention in care in the rapid ART period. 319 
Secondly, a change that was implemented contemporaneously with rapid ART was the switch 320 
to DTG-based ART. This is unlikely to influence ART timing but is likely to have contributed 321 
to the more rapid viral suppression in the later cohort. Median time from ART initiation to viral 322 
suppression was slightly shorter in the rapid ART period when DTG was the standard ART 323 
regimen but did not account for the major difference in time from linkage to viral suppression. 324 
Finally, results may not be directly generalizable to all African or LMIC settings. Our study 325 
sites were rural or peri-urban, and the study population 60% women with a median age of 326 
almost 35 years and a relatively high median baseline CD4 count of 350 cells/µL. Although 327 
the study was conducted in public facilities, extra trained staff was placed by the Ministry of 328 
Health (with support from the study team) to deal with congestion at the clinics. Additional 329 
staff trainings were provided, and a higher level of monitoring and supervision was performed 330 
than is standard in the Government sector in Botswana. Most HIV testing was community 331 
based, with testing staff receiving specific training on delivering counselling messages 332 
facilitating rapid ART initiation. 333 
In conclusion, we have shown that offering same day ART to individuals presenting for 334 
HIV care in public sector clinics in Botswana leads to high rates of ART initiation, significantly 335 
reduced time from linkage to starting ART, and significantly reduced time to virological 336 
suppression. Rapid ART initiation was safe, even in the absence of baseline blood test results, 337 
and the benefits were sustained, with comparable rates of retention in care and viral suppression 338 
after 1 year of ART to those achieved with traditional models of care.  339 
340 
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Tables 465 
Table 1. Baseline characteristics of study participants 466 






(years, median, IQR) 
37 (29-45) 33 (26-41) <0.001 
Sex  
(% male, n) 
38.2% (656) 45.1% (361)  0.001 
Weight* 
(kg, median, IQR) 
61 (54-71) 61 (54-69) 0.990 
New HIV+ve diagnosis†  
(% newly diagnosed HIV, n) 
47.3% (812) 60.5% (484) <0.001 
Prior ART default  
(% ART experienced, n) 
6.3% (108) 6.8% (54) 0.020 
Baseline CD4 cell count‡  
(cells/µL, median, IQR) 
342 (232-472) 344 (202-504) 0.647 
Baseline creatinine 
(mmol/L, median, IQR) 
67 (55-80) 66 (55-77) 0.523 
Baseline haemoglobin 
(g/dL, median, IQR) 
13.1 (11.8-14.3) 13.4 (12.1-14.8) 0.001 
Baseline alanine transaminase 
(IU, median, IQR) 
17 (13-23) 17 (12-24) 0.777 
Restricted to patients eligible for ART initiation (see methods section). 
*Weights were missing in 342/1,717 participants in the pre-Rapid ART group and 232/800 participants in 
the Rapid ART group. 
†Patients diagnosed as HIV infected for the first time at study baseline testing.  
‡ Baseline CD4 counts were missing in 41/1,717 participants in the pre-Rapid ART group and 335/800 
participants in the Rapid ART group. 
P-values for comparisons of proportions were derived from a hierarchical mixed effects regression model 
incorporating a random effects term for community. P-values for comparisons of medians were derived 
from ranked testing (F-testing) of Somers’ D parameter estimates accounting for clustering by site 
(comparable to a Kruskall-Wallis test). 
 ART: antiretroviral therapy. IQR: interquartile range. n: number. IU: International Units. 
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Supplementary Table 1. Outcomes in study participants initiated on ART with abnormal creatinine clearance. 
 











1 Year Viral 
Load 
1. 60 years Male 84 cells/µL 
TDF/FTC, 
DTG 
0 50 mL/min 82 mmol/L Remained on TDF. Stable on ART. Alive and well at 1 year. Alive < 400 copies/ml 
2. 45 years Male 478 cells/µL 
TDF/FTC, 
DTG 
0 46 mL/min 120 mmol/L 
Remained on TDF. Repeat creatinine=69 mmol/L at week 10. 
Stable on ART. Alive and well at 1 year. 
Alive < 400 copies/ml 
3. 28 years Male 615 cells/µL 
TDF/FTC, 
DTG 
0 59 mL/min 129 mmol/L 
Remained on TDF. Repeat creatinine=70 mmol/L at week 4. 
Stable on ART. Alive and well at 1 year. 
Alive < 400 copies/ml 
4. 61 years Male 94 cells/µL 
TDF/FTC, 
DTG 
0 49 mL/min 91 mmol/L 
Remained on TDF. Repeat creatinine=91mmol/L at week 2. Died 
week 20. Cause of death unknown. 
Died NA 
5. 32 years Male 17 cells/µL 
TDF/FTC, 
DTG 
0 20 mL/min 369 mmol/L 
Switched to non TDF containing regimen (Abacavir) day 12. 
Repeat creatinine=98 mmol/L at week 2 and 65 mmol/L week 12. 
Stable on ART. Alive and well at 1 year. 
Alive <400 copies/ml 
6. 41 years Female 213 cells/µL 
ABC, 3TC, 
DTG 
0 56 mL/min 113 mmol/L 
Started on non TDF containing regimen (Abacavir) as history of 
abnormal renal function. Died week 46 due to Cervical cancer 
Died NA 
7. 33 years Female 154 cells/µL 
ABC, 3TC, 
DTG 
0 32 mL/min 137 mmol/L 
Started on non TDF containing regimen (Abacavir) as history of 
abnormal renal function. Stable on ART. Alive and well at 1 year. 
Alive < 400 copies/ml 
8. 54 years Male 9 cells/µL 
TDF/FTC, 
DTG 
7 51 mL/min 91 mmol/L 
Switched to non TDF containing regimen (Abacavir) month 4. 
Stable on ART. Alive and well at 1 year. 
Alive < 400 copies/ml 
9. 57 years Female 448 cells/µL 
TDF/FTC, 
DTG 
9 51 mL/min 68 mmol/L 
Switched to non TDF containing regimen (Abacavir) month 4. 
Stable on ART. Alive and well at 1 year. 77 week 4 
58 week 8 
Alive < 400 copies/ml 
10. 63 years Female 480 cells/µL 
TDF/FTC, 
DTG 
65 46 mL/min 132 mmol/L 
109.4 week 8. Switched to non TDF containing regimen 
(Abacavir) month 3. Stable on ART. Alive and well at 1 year. 
Alive < 400 copies/ml 
11. 53 years Male 151 cells/µL 
TDF/FTC, 
DTG 
53 34 mL/min 137 mmol/L 
214 week 8. Switched to non TDF containing regimen (Abacavir) 
week 7. Stable on ART. Alive and well at 1 year. 
Alive < 400 copies/ml 
12. 41 years Female 85 cells/µL 
ABC, 3TC, 
DTG 
487 40 mL/min 86 mmol/L 
Started on non TDF containing regimen (Abacavir) due to 
abnormal renal function. Stable on ART. Alive and well at 1 year. 
Alive Unknown 
ART:Antiretroviral therapy.  TDF: tenofovir. FTC: emtricitabine. DTG: dolutegravir. ABC: abacavir. NA: not applicable.
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Figure Legend 
Figure 1. Patient flow diagram. Prior to the introduction of universal antiretroviral therapy 
(ART) in June 2016 an individual was eligible for ART when (1) CD4 was <350 cells/µL or 
they met criteria for WHO clinical stage III or IV, based on Botswana’s national guidelines; or 
(2) if they met the BCPP expanded ART eligibility criteria of CD4 <500 cells/µL or CD4 >500 
cells/µL and viral load (VL) > 10,000 copies/µL. *The cumulative proportion on ART (as in 
Figure 2) was 93.5% as not all individuals in the Rapid ART group had completed 1 year of 
follow-up by the time of data censoring. 
 
Figure 2. Time from linkage (first ART clinic visit) to ART initiation. Figure 2.a. shows 
cumulative time to ART during the pre-Rapid ART cohort (in blue), and following the 
introduction of Rapid ART (in red), with cumulative probabilities at 1 day, 1 week, 2 weeks, 1 
month, 3 month, and 1 year in the table below. The hazards of ART initiation derived from the 
hierarchical Cox proportional hazards model accounting for clustering by community and 
adjusted for age, sex, CD4 count, and whether individuals were newly diagnosed with HIV or 
had a previously known diagnosis was 3.83 (95% confidence interval [CI] 3.41-4.32), p<0.001. 
Figure 2.b. shows the results of an interrupted time series analysis using log transformed 
monthly aggregate data. There was a significant decrease in time from linkage to ART initiation 
in the month following introduction of rapid ART initiation guidelines (∆=-0.78 log10days, 
95% CI -0.93 to -0.63 log10days, p<0.001). Months with less than 15 ART initiations in total 
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Figure 3. Retention in care and virological suppression at 12 months following standard or 
rapid ART initiation. (ART: antiretroviral therapy. VL: viral load). In an analysis restricted 
just to those who initiated ART within 1 day of linkage (“same day”) during the rapid ART 
period, 96.9% (379/391) of individuals were retained at 1 year; 1 year VLs were recorded in 
93.6% (366/391) of individuals initiating same day, with a 97.5% viral suppression rate in 
those with a VL result, and 91.3% (357/391) individuals overall in care and with a 
documented VL <400 copies/ml after 1 year of ART. 
 
Supplementary Figure S1. Time from linkage (first ART clinic visit) to ART initiation pre 
and post the introduction of Rapid ART stratified by i) prior HIV status (new or previously 
known diagnosis at study entry); ii) baseline CD4 cell count (dichotomized at 200 cells/µL); 
iii) sex; and iv) age (16-24 years or 25 years and older). Introduction of Rapid ART guidelines 
led to significantly faster rates of ART initiation in all strata. The stratified analyses of ART 
timing showed no significant interactions between rapid ART introduction and prior HIV status 
(new or known), sex, or age (less than 25 years or 25 years and older); however very weak 
evidence for an interaction was found between the effect of rapid ART introduction on ART 
timing and baseline CD4 count (panel 2). Prior to rapid ART introduction individuals with 
CD4 cell counts 200 cells/µL were initiated on ART significantly more rapidly following 
linkage than those with CD4 counts >200 cells/µL. Although the introduction of rapid ART 
initiation guidelines led to significantly more rapid ART initiation in both the group with CD4 
cell counts 200 cells/µL and those with CD4 counts >200 cells/µL, the impact was less 
marked in the low CD4 count group due to the already more rapid ART initiation rates during 
the standard ART period in this group (hazard ratio 0.81, 95%CI 0.63-1.04, p=0.10). 
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3657 HIV +ve individuals 
identified not on ART 
3282 (89.7%) Linked to 
care 
374 Linked to care at non-study 
site without known linkage date. 
Excluded from further analyses 
2108 Pre-Rapid ART  800 Rapid ART 
1717 HIV +ve individuals 
linked and eligible for ART 
800 HIV +ve individuals 
linked and eligible for ART 
 
1532 (89.2%) initiated by 1 
year 
744 (93.0%*) initiated by 1 
year 
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Figure 2.a.  
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initiated ART by end of 
follow-up 
1601/1627 (98.4%) 
retained after 12 months 
of ART 
1509/1627 (92.7%)    
had VL testing at one 
year  
Overall 1472/1627 
(90.5%) on ART with 
documented VL<400 
copies/mL at 1 year 
1627 initiated >12 
months prior to 
data censoring  
1472/1509 (97.5%) 
VL<400 copies/mL 
Pre-Rapid ART Rapid ART 
Same Day ART* 
454 initiated  
“Same Day” 
379/391 (96.9%) 
retained after 12 months 
of ART 
366/391 (93.6%)  
had VL testing at one 
year 
Overall 357/391  
(91.3%) on ART with 
documented VL<400 
copies/mL at 1 year 
357/366 (97.5%)  
VL<400 copies/mL 
751/800 (93.9%) 
initiated ART by end of 
follow-up 
610/631 (96.7%) 
retained after 12 months 
of ART 
592/631 (93.8%)         
had VL testing at one 
year 
Overall 578/631  
(91.6%) on ART with 
documented VL<400 
copies/mL at 1 year 
578/592 (97.6%)  
VL<400 copies/mL 
631 initiated >12 
months prior to 
data censoring  
391 initiated >12 
months prior to 
data censoring  
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Supplementary Figure S1. 
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Research in context 
Evidence before this study 
There is strong evidence for both the patient-level health benefits of ART and public health 
benefits of ART resulting from reduced HIV transmission.  To fully realise these benefits, it is 
critical that individuals who are diagnosed with HIV infection rapidly initiate ART. However, 
data from low- and middle-income (LMIC) settings has demonstrated high rates of loss from 
the care cascade between HIV testing and ART initiation, or substantial delays to initiation of 
treatment. A potential way to increase rates of ART initiation is to offer same-day ART to all 
individuals at their initial clinic visit. We searched PubMed, EMBASE, and PubMed Central 
for studies published between Jan 1, 2000, and July 31, 2019, investigating the acceptability, 
feasibility, safety, and outcomes of rapid or same-day antiretroviral therapy (ART) initiation 
in HIV-infected individuals presenting to treatment services. Several randomized controlled 
trials from LMIC settings have shown that rapid ART initiation, including treatment initiation 
at the first clinic visit, is acceptable and feasible, and can increase rates of ART initiation, 
retention in care, and virological suppression. However, prior trials included enhancements to 
care beyond changes to ART timing, and also included CD4-based eligibility criteria, 
potentially limiting their generalizability to more routine care settings in the test and treat era.  
 
Added value of this study 
We were able to evaluate the acceptability, feasibility and outcomes of rapid ART initiation 
with the offer of ART at first clinic visit in the context of the cluster-randomized Botswana 
Combination Prevention Project (BCPP). Simplified rapid ART initiation with the offer of 
same day treatment at first ART clinic visit was acceptable and feasible in public ART clinics 
in Botswana. Following the introduction of rapid ART guidelines, the proportion of patients 
established on ART within 1 month from clinic linkage increased from 49% to 85%, and from 
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89% to 94% at 1 year. The median time from clinic linkage to viral suppression was 
significantly reduced. Rates of retention in care and viral suppression were similarly high in 
individuals initiated on ART prior to the introduction of rapid ART and those initiated during 
the rapid ART period, with documented viral suppression after 1 year of ART in over 90% of 
individuals in both groups. To the best of our knowledge, these are the first data reporting the 
outcomes of rapid ART initiation in a routine LMIC care setting, without baseline screening 
blood tests, point-of-care CD4 counts, or additional clinical assessments. Our findings add to 
the accumulating evidence demonstrating the feasibility, acceptability, and safety of rapid ART 
initiation in LMIC settings, and indicate that benefits of rapid ART initiation are sustained over 
time. 
 
Implications of all the available evidence 
The more rapid ART initiation and shorter time from clinic linkage to viral suppression 
observed following implementation of rapid ART initiation guidelines are likely to have both 
individual- and population-level benefits. The findings support recent World Health 
Organisation guidance recommending rapid ART initiation and could help HIV-treatment 
programmes in Africa and globally reach the ambitious UNAIDS 90-90-90 targets. 
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